Author | David S. Hong, MD | OncLive

Author | David S. Hong, MD

Articles

Dr. Hong on Moving Tisotumab Vedotin to Frontline Therapy for Cervical Cancer

October 18, 2019

Video

David S. Hong, MD, discusses the potential of moving tisotumab vedotin (HuMax-TF-ADC) to the frontline setting in cervical cancer.

Dr. Hong on the Mechanism of Action of Tisotumab vedotin in Cervical Cancer

June 25, 2019

Video

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

Dr. Hong on the Design of the InnovaTV 201 Trial in Cervical Cancer

May 23, 2019

Video

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the InnovaTV 201 trial in cervical cancer.

Dr. Hong on the Safety Profile of Tisotumab Vedotin in Cervical Cancer

May 16, 2019

Video

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

x